Cloud-based Software As A Medical Device (SaMD) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Cloud-based Software As A Medical Device (SaMD) Market Trends and Insights

Growing Clinical Adoption of AI-Enabled Diagnostic Software

The FDA reported 295 new AI-enabled medical device authorizations in 2025, bringing the cumulative total to 1,451 devices by December 30, 2025. This growth supported broader clinical familiarity with software used for diagnosis, triage, and image interpretation, although authorization still required local validation and implementation. Radiology accounted for 1,104 of the 1,451 cumulative FDA-listed AI-enabled devices by the end of 2025, underscoring its established role in clinical AI adoption. The 2024 PCCP guidance gave developers a defined route to describe planned model modifications and controls in a marketing submission, while cloud delivery supported version management, monitoring, and rollback processes.^{[1]U.S. Food and Drug Administration, “Artificial Intelligence-Enabled Medical Devices,” U.S. Food and Drug Administration, fda.gov}

Expansion of Remote Patient Monitoring and Virtual Care

Remote patient monitoring increasingly connected biosensor data with clinical review and patient support. The FDA launched the Technology-Enabled Meaningful Patient Outcomes pilot in December 2025, and Dexcom became its first participant on July 22, 2026. Dexcom’s program combined data from Dexcom G7 and Stelo biosensors with nutritional, sleep, and activity inputs for prediabetes and Type 2 diabetes interventions. A National Institute for Health and Care Research horizon scan identified 576 emerging wearable technologies under clinical evaluation for chronic disease management, including 25 novel technologies and 14 with a CE mark or FDA approval.^{[2]National Institute for Health and Care Research, “Horizon Scan of Wearable Devices for Chronic Disease Management,” National Institute for Health and Care Research, io.nihr.ac.uk}

Healthcare Provider Demand for Scalable Cloud Infrastructure

Health systems are shifting procurement in the cloud-based software as a medical device market toward services that reduce dependence on dedicated local storage and computing capacity. GE HealthCare introduced its Genesis cloud portfolio in March 2025, with vendor-neutral archive, edge-to-cloud storage, and data migration capabilities. The company stated that it aimed to triple its cloud-enabled product offerings by 2028. Cloud services allow providers to use subscription- or utilization-based models and integrate imaging, AI tools, and workflow functions into one enterprise procurement arrangement.

Increasing Use of Real-World Data and Real-World Evidence

Real-world data is becoming more central to clinical evidence generation and product monitoring. In June 2026, Tempus announced the publication of a multi-center validation of its FDA-cleared ECG-AF model in Heart Rhythm. The study addressed 1-year atrial fibrillation risk prediction across diverse patient populations in a clinical setting. Connected cloud platforms can capture post-deployment performance data, support product oversight, and help vendors build evidence across multiple care settings while meeting privacy and quality requirements.

Cybersecurity, Data Privacy, and Cross-Border Health-Data Restrictions

The FDA issued final cybersecurity guidance for medical devices on June 27, 2025, covering cybersecurity design, documentation, and vulnerability management expectations for connected devices. The Quality Management System Regulation became effective on February 2, 2026, aligning FDA quality system requirements with ISO 13485:2016. These requirements increased compliance responsibilities for developers of cloud-hosted medical software. Data protection rules may require vendors to adjust where they store and process health information, while national requirements can limit the use of a single cloud architecture across every market. These obligations favor providers with established security, quality, and local compliance capabilities.

Clinical Validation, Liability, and Workflow-Integration Complexity

Most clinical software under EU MDR Rule 11 requires classification and conformity assessment based on its clinical role. Evidence requirements, technical documentation, and review processes can increase the time and cost of product introduction. Deployment in the cloud-based software as a medical device market can stall when interfaces, user authentication, alerts, and clinical processes do not align with hospital environments. Responsibility for an AI-assisted clinical decision may involve the software developer, the health system, and the clinician, making some providers cautious when evaluating new applications. Vendors can reduce procurement friction by providing clear intended-use information, performance monitoring tools, bias disclosures, and practical integration support.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Deployment: Cloud Services Lead While On-Premises Systems Serve Sovereignty Needs

Cloud-based deployment held 63.22% of the cloud-based software as a medical device market share in 2025. Health systems use cloud deployment to manage imaging archives, analytics capacity, and software update cycles without relying solely on local infrastructure. This model supports subscriptions and pay-per-scan arrangements, helping providers align technology spending with usage while avoiding local system replacements solely to access new analytical capacity. Vendors also use cloud deployment to distribute updates and monitor software performance across multiple sites.

On-premises deployment is forecast to expand at an 18.93% CAGR from 2026 to 2031. Demand comes from air-gapped government hospitals, defense health facilities, and markets with data sovereignty requirements. Hybrid systems provide a practical middle path for academic medical centers that retain local graphics processing units for model development while using cloud inference in clinical settings. GE HealthCare’s Genesis portfolio was introduced to support cloud and hybrid workflows alongside existing capital investments.

By Device Type and Access Channel: Wearables Connect Patient Data With Clinical Review

Wearable devices accounted for 35.23% of revenue in 2025, making them the largest category in this segmentation. Cardiac monitoring, continuous glucose sensing, and pulse oximetry remain key use cases. Wearables collect frequent measurements that can move to software platforms in the cloud-based software as a medical device market for review and clinical action. Their value increases when data enters structured clinical workflows that support review, assignment, and documentation.

Web-based clinical workstations are forecast to grow at a 17.67% CAGR from 2026 to 2031. Zero-footprint viewers and cloud-native picture archiving systems reduce the need for site-specific hardware. In March 2026, GE HealthCare received FDA 510(k) clearance for View, a cloud-based diagnostic viewer designed to provide browser access for radiologists. Smartphones, tablets, personal computers, and connected sensors complete the remaining access mix, with smartphones gaining relevance in lower-acuity primary care settings in Asia-Pacific.

By Application: Screening Remains Largest While Chronic Care Expands

Screening and early detection represented 31.34% of revenue in 2025. This segment includes lung cancer CT screening, diabetic retinopathy detection, and early sepsis identification. These applications benefit from the high number of AI-enabled devices in imaging and diagnostic workflows, where clinicians routinely review images and findings before final decisions. Early detection tools fit existing clinical processes when they provide a clear clinician review step.

Chronic disease management is forecast to expand at an 18.35% CAGR through 2031. Diabetes, heart failure, chronic obstructive pulmonary disease, and hypertension require repeated monitoring beyond periodic clinical visits. Cloud software in the cloud-based software as a medical device market can organize connected-device data and support alerts or treatment follow-up. In June 2026, GE HealthCare received FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0, an AI-enabled radiation therapy planning solution with expanded clinical capabilities.

By Clinical Specialty: Radiology Has an Installed Base and Cardiology Adds Momentum

Radiology held a 28.88% revenue share in 2025, the largest share among clinical specialties. The specialty has a long history of digital image management and radiologist review of machine-generated findings. The FDA listed 1,104 radiology devices among its 1,451 cumulative AI-enabled medical device authorizations by the end of 2025. This installed base gives radiology vendors workflow familiarity and broad clinical data resources.

Cardiology is forecast to advance at a 17.78% CAGR from 2026 to 2031. AI-assisted ECG interpretation, cardiac image analysis, and risk stratification can use signals from connected devices and clinical records. The specialty suits cloud systems in the cloud-based software as a medical device market because many cardiac conditions require continuing observation rather than a single diagnostic review. Oncology, neurology, ophthalmology, pathology, respiratory care, diabetes care, mental and behavioral health, and women’s health also widen the clinical range.

By End User: Hospitals Lead Adoption While Laboratories Increase Demand

Hospitals and clinics accounted for 47.89% of revenue in 2025. These organizations are the main deployment sites for enterprise imaging AI, clinical decision support, and electronic health record-linked tools. They also have defined vendor review processes and IT teams that can manage integration. Hospitals remain the central commercial route for vendors seeking broad clinical deployment across departments, users, and connected service lines.

Diagnostic laboratories are forecast to grow at a 16.45% CAGR through 2031. Digital pathology, liquid biopsy analysis, and genomic sequencing create demand for systems that can process multimodal diagnostic information at scale. Tempus reported full-year 2025 revenue of USD 1.27 billion, an 83% increase from the prior year, highlighting commercial activity in AI-enabled laboratory diagnostics. Ambulatory and specialist centers, imaging centers, academic institutions, and research organizations also use cloud platforms for consultation support, monitoring, validation studies, and data collaboration.

Geography Analysis

North America held a 40.56% revenue share in 2025, supported by the largest concentration of FDA-cleared AI-enabled medical devices and significant health system spending on digital care. The FDA’s list reached 1,451 authorized AI-enabled devices by the end of 2025. The United States finalized PCCP guidance in December 2024 and launched the TEMPO pilot in December 2025. Longstanding electronic health record, imaging, and laboratory data may support further algorithm development, although developers still need to manage data access, representativeness, and appropriate use.

Europe is shaped by EU MDR classification rules and a varied reimbursement environment. Germany’s DiGA pathway has allowed qualifying digital health applications to be prescribed and reimbursed through statutory health insurance, while France and Belgium have also developed digital health reimbursement pathways. The cloud-based software as a medical device market in Europe must address data protection, interoperability, and national assessment requirements. Germany, the United Kingdom, France, Italy, and Spain account for much of the region’s revenue, but suppliers still need to align reimbursement, procurement, and regulatory approaches with each national system. The European Health Data Space requirements will require manufacturers to plan for interoperability and logging capabilities in cloud platforms before 2029.

Asia-Pacific is forecast to register the highest regional CAGR of 17.56% from 2026 to 2031, driven by hospital digitization, regulatory development, and shortages of specialist physicians supporting demand for AI-assisted diagnosis in the cloud-based software as a medical device market. China released the revised YY/T 1406-2026 standard on March 17, 2026, covering risk management across the medical device software lifecycle and taking effect in March 2027.